Abstract

Background: Recent evidence suggests that higher rifampicin (R) doses may improve tuberculosis (TB) treatment outcome. Methods: In this observational cohort study we evaluated all TB patients who were treated with high-dose R (> 10 mg/kg daily) in our reference centre, from 2008- 2018. Indications, achieved plasma R exposures, safety and tolerability were evaluated. Results: 88 patients were included. The main indications were low plasma concentrations (64.7%) and severe illness (29.5%), including central nervous system TB. Adjusted R dosages ranged from 900 mg to a maximum of 2400 mg (corresponding to 32 mg/kg) per day. Patients with severe illness received high-dose R immediately, the others had a higher dosage guided by therapeutic drug monitoring. 4 patients developed hepatotoxicity, of which two were proven due to isoniazid. Re-introduction of high-dose R was successful in all four. 87 patients tolerated high-dose R well throughout treatment. Only 1 patient required a dose reduction due to gastro-intestinal disturbance. Conclusion: High-dose R, used in specific groups of patients in our clinical setting, is safe and well-tolerated for the whole treatment duration. Measurement of drug exposures could be used as a tool/guide to increase R dosage if a reduced medication absorption or a poor treatment outcome is suspected. Pending the results from clinical trials, we suggest to administer high-dose R to patients with severe manifestations of TB or low R exposure to improve treatment outcome.

Highlights

  • Rifampicin plays a key role in tuberculosis (TB) treatment regimens, due to its bactericidal and sterilizing capacity

  • Patients with severe illness received high-dose rifampicin immediately, the others had a higher dosage guided by therapeutic drug monitoring

  • Measurement of drug exposures could be used as a tool/guide to increase rifampicin dosage if a reduced medication absorption or a poor treatment outcome is suspected

Read more

Summary

Introduction

Rifampicin plays a key role in tuberculosis (TB) treatment regimens, due to its bactericidal and sterilizing capacity. It was introduced in the early 1970s at a dose of 10 mg/kg (with a maximum of 600 mg) once daily, mainly because of financial considerations and fear of toxicity[1]. Several studies have suggested that the standard dose of 10 mg/kg rifampicin is suboptimal and at the lower end of the dose-response curve[1, 2]. In TB meningitis, an increased intravenous dosage of 13 mg/kg rifampicin resulted in a 50% reduced mortality in a phase II RCT in Indonesia [12]. Recent evidence suggests that higher rifampicin doses may improve tuberculosis (TB) treatment outcome.

Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.